India Launches 7-Minute Cancer Shot That Could Transform Lung Cancer Treatment - Who Can Benefit?

A newly launched immunotherapy injection for lung cancer is offering fresh hope to patients in India by significantly reducing treatment time and improving convenience. Pharmaceutical giant Roche has introduced the subcutaneous version of its immunotherapy drug atezolizumab, marketed under the brand name Tecentriq, for patients with non-small cell lung cancer (NSCLC). Doctors say the injectable cancer treatment could transform how immunotherapy is administered, especially for patients who struggle with lengthy intravenous (IV) infusions or fear traditional chemotherapy side effects. Doctors say many patients who have been diagnosed with advanced lung cancer that has already metastasised can opt for immunotherapy. Instead of the standard IV infusion,

doctors recommend the newly launched under-the-skin injection version of the therapy for treatment.Also read: PCOD and Heart Disease: The Dangerous Link Many Young Women Ignore

What is the 7-minute immunotherapy shot?

The new subcutaneous injection is designed for patients with non-small cell lung cancer, which accounts for the majority of India’s estimated 81,000 annual lung cancer cases. Unlike chemotherapy, which directly attacks cancer cells, immunotherapy boosts the body’s immune system to identify and destroy cancer cells more effectively. The injectable version of atezolizumab can be administered in just seven minutes through an injection in the thigh by trained nursing staff in hospital outpatient departments. Previously, patients needed lengthy intravenous infusions that often required extended hospital visits. Doctors say the shorter administration time has improved treatment compliance and patient comfort.

Who can receive this treatment?

The therapy is specifically intended for NSCLC patients whose tumours express PD-L1 receptors. Experts estimate that nearly half of all patients with non-small cell lung cancer may qualify for this targeted immunotherapy treatment. Studies have shown that atezolizumab can improve progression-free survival, increase overall survival rates, and reduce the risk of death in eligible lung cancer patients.

Why are the doctors calling it a game-changer?

Oncologists believe the injectable version could reduce the burden on both patients and hospitals. Hospitals can reportedly administer the subcutaneous injection to multiple patients in the time it previously took to complete one IV infusion session. Global studies have also found that four out of five patients preferred the subcutaneous injection over IV therapy because of greater convenience, shorter hospital stays, and fewer infusion-related side effects. Experts say the launch marks an important advancement in cancer care in India, where rising lung cancer cases continue to place enormous pressure on healthcare systems. While immunotherapy is not suitable for every patient, doctors believe innovations like rapid injectable treatments could improve quality of life and make advanced cancer care more accessible and manageable for eligible patients.